TORONTO / Feb 27, 2025 / Business Wire / Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens,1-3 delivering the same exceptionally comfortable wearing experience,5 now in a –2.75D cylinder offering.
Astigmatic patients, making up 47% of the patient population,6 are even more likely to suffer from dryness and discomfort.7 As the leading cause of dropout,8 contact lens discomfort not only impacts patients’ ability to enjoy freedom from glasses but can also affect their day-to-day lives. TOTAL30 for Astigmatism with expanded parameters is bridging the divide, providing patients with proven stability, and TOTAL comfort all month long,5 at an affordable price.
“Alcon’s continued investment in reusable innovation aims to better serve the 61%9 of Canadian contact lens wearers choosing reusable lenses,” said Jeroen Bastemeijer, General Manager of Alcon Canada. “By introducing expanded -2.75D cylinder parameters in TOTAL30 for Astigmatism, Alcon facilitates Eye Care Professionals (ECPs) in addressing the diverse needs of today’s patients, allowing them to experience TOTAL comfort all month long.”5
As with the entire WaterInnovations™ Toric family, TOTAL30 for Astigmatism lenses in expanded parameters are equipped with Alcon’s proprietary PRECISION BALANCE 8|4® lens design,4,10,11 providing the on-eye stability astigmatic contact lens wearers need for exceptionally clear and stable vision,12 as well as a 95% first lens fit success rate.4* They also feature Class 1 UV blocking against UVA and UVB rays,13-15† and Blue-Violet Light (BVL) filtration‡ for reduced exposure.13
Alcon’s dedication to expanding access to eye care includes ensuring all patients are equipped with the necessary information they need to make eye health decisions. That is why ECPs will be able to utilize informative materials about TOTAL30 for Astigmatism in expanded parameters in English and French. For access to the materials, ECPs can reach out to their Alcon representatives, and for more ECP to patient digital resources, visit AlconVisionBrandLibrary.com
“It is truly exciting that the reusable lens I have come to trust most for my astigmatic patients is now available in expanded cylinder parameters,” said Dr. Pavan Avinashi, Doctor of Optometry at the Hollyburn Eye Clinic in Vancouver. “Total30 has redefined the reusable contact lens market, providing all the innovations of Water Gradient Technology,2,3 UV Blocking,13-15† Blue-Violet Light Filtration,13‡ quick time to settle,4 and incredible first lens fit success.4* With the new -2.75D cylinder options, I can now fit close to 100% of my astigmatic patients,** allowing even more people to experience this impressive technology."
TOTAL30 for Astigmatism in expanded parameters is now available across Canada. For more information, please visit www.alcon.ca
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca
References
*Based on lens movement, centration and orientation at initial fitting.
**Covers 99% of astigmats. Coverage of astigmatic patients with a -3.00D cylinder or lower.
†UV absorbing contact lenses are NOT substitutes for protective UV absorbing eyewear, such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. The patient should continue to use UV absorbing eyewear as directed.
‡There is no demonstrated clinical benefit to reduction in blue-violet light at wavelengths below 450 nm. BVL testing done on lehfilcon A sphere lenses.
See product instructions for complete wear, care, and safety information. Rx only.
Connect with us on
Facebook
LinkedIn
Last Trade: | US$88.14 |
Daily Change: | 1.33 1.53 |
Daily Volume: | 153,298 |
Market Cap: | US$43.590B |
February 25, 2025 February 24, 2025 February 19, 2025 November 12, 2024 November 07, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load